Patent: 7,303,747
✉ Email this page to a colleague
Summary for Patent: 7,303,747
Title: | Use of VEGF inhibitors for treatment of eye disorders |
Abstract: | Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy. |
Inventor(s): | Wiegand; Stanley J. (Croton-on-Hudson, NY), Papadopoulos; Nicholas J. (LaGrangeville, NY), Yancopoulos; George D. (Yorktown Heights, NY), Fandl; James P. (LaGrangeville, NY), Daly; Thomas J. (New City, NY) |
Assignee: | Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) |
Application Number: | 11/218,234 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,303,747 |
Patent Claims: | see list of patent claims |
Details for Patent 7,303,747
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | November 18, 2011 | ⤷ Sign Up | 2039-02-26 |
Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | August 16, 2018 | ⤷ Sign Up | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 7,303,747
Country | Patent Number | Estimated Expiration |
---|---|---|
Argentina | 044938 | ⤷ Sign Up |
Austria | E293164 | ⤷ Sign Up |
Austria | E417928 | ⤷ Sign Up |
Austria | E427962 | ⤷ Sign Up |
Austria | E486091 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |